Recon: Senate confirms Monica Bertagnolli as NIH director; Sen. Sanders pushes for hearing with top pharma executives

• Bertagnolli confirmed as new head of National Institutes of Health (Washington Post) (The Hill)
• Ozempic side effects 'well-known,' Novo Nordisk argues (Reuters)
• Judge trims US lawsuit accusing Cencora of fueling opioid epidemic (Reuters)
• HHS secretaries Becerra, Azar face off on lowering drug prices (STAT)
• FDA Abortion Pill Actions See Fresh Challenge From Red States (Bloomberg Law)
• US orders Puerto Rico drug distribution company to pay $12 million in opioid case (Associated Press)
• Sen. Bernie Sanders moves toward another hearing with pharma CEOs (STAT)
• Drug shortages and the supply chain are a matter of national security, experts say (STAT)
• Pulse oximeters’ inaccuracies in darker-skinned people require urgent action, AGs tell FDA (STAT)

• UK’s ‘Pioneering’ Medicines Repurposing Program Delivers First License (Pink Sheet)
• EFPIA: One Fifth Of Future Products ‘Unviable’ Under EU’s Plans To Modulate Regulatory Data Protection (Pink Sheet)
• EMA Consults On Guidance On Vaccine Trials In Immunocompromised Individuals (Pink Sheet)
• Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines (STAT)
• The doping of Sanofi's financial communications in the PNF's sights (La Lettre)
• Intellectual Property Negotiations Belong at WTO, European Countries Tell Pandemic Accord Negotiations (Health Policy Watch)

• Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule (BioSpace)
• Astellas shows enough data for eye treatment to support expanded use, but still lags competitor (STAT)
• FDA cites cancer links in seeking to withdraw approval of antibiotic used in pigs (STAT)
• Ventyx stock craters after lackluster mid-stage trial results for psoriasis drug (STAT)
• Your morning biotech news roundup (STAT)
• Johnson & Johnson to submit application to start trials for surgical robot (Reuters)
• Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 (Reuters)
• Novo Nordisk to present new data from weight-loss, diabetes trials (Reuters)
• mRNA’s next trick? Reprogramming off-the-shelf cell therapies for cancer and autoimmune diseases (Endpoints)
• Lilly backs OrsoBio's $60M Series A for PhII trials in obesity and NASH (Endpoints)
• Novartis slots PhI cardiovascular candidate into pipeline, paying Korean partner $80M upfront (Endpoints)
• WuXi XDC eyes $470.5M IPO to fuel manufacturing expansions at home and abroad (Fierce)
• Imbria touts PhII success in hypertrophic cardiomyopathy, adding fuel to overall efficacy profile (Endpoints)
• MarketingRx roundup: Sanofi, Regeneron renew Dupixent asthma effort; Bausch Health battles seasonal affective disorder (Endpoints) 
• Gilead, Arcus’ PhII gastroesophageal cancer data argue for TIGIT antibody drug class potential (Endpoints)

• Remote patient monitoring helped manage hypertension better, but at a higher cost (STAT)
• A fertility clinic failure destroyed my chance at motherhood (STAT)
• The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint (STAT)
• Zimmer Biomet’s Ivan Tornos sets priorities for first year as CEO (MedTech Dive)
• Diabetes tech firms focusing on Type 2 patients (MedTech Dive)

• California Low-Cost Insulin Faces Delays After Price-Cap Veto (Bloomberg Law)
• FTC’s Lina Khan makes a stop at Y Combinator, how telehealth helps rural America (STAT)
• Government looks to tinker with new caps on Medicare Advantage broker payments (STAT)
• US FTC disputes listing for more than 100 patents in FDA Orange Book (Reuters)
• US CDC to expand surveillance of traveler samples for respiratory viruses (Reuters)
• Pfizer gathers Covid campaign 'icons' Martha Stewart, John Legend, Travis Kelce and more for latest booster push (Endpoints)